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Abstract
Background and Objective Patients from a previous study
of neuropathic pain (NP) in the Spanish primary care
setting still had symptoms despite treatment. Subsequently,
patients were treated as prescribed by their physician and
followed up for 3 months. Since pregabalin has been
shown to be effective in NP, including refractory cases, the
objective of this study was to assess the effectiveness of
pregabalin therapy in patients with NP refractory to pre-
vious treatments.
Methods This was a post hoc analysis of pregabalin-naı¨ve
NP patients treated with pregabalin in a 3-month follow-up
observational multicenter study to assess symptoms and
satisfaction with treatment. Patients were evaluated with
the Douleur Neuropathique en 4 questions (DN4), the Brief
Pain Inventory (BPI) and the Treatment Satisfaction for
Medication Questionnaire (SATMED-Q) overall satisfac-
tion domain.
Results 1,670 patients (mean age 58 years, 59 %
women), previously untreated or treated with C1 drug
other than pregabalin, were treated with pregabalin (37 %
on monotherapy). At 3 months, pain intensity and its
interference with activities decreased by half (p \ 0.0001),
while the number of days with no or mild pain increased by
a mean of 4.5 days (p \ 0.0001). Treatment satisfaction
increased twofold (p \ 0.0001). Patients with a shorter
history of pain and those with neuralgia and peripheral
nerve compression syndrome (PCS) as etiologies had
the highest proportion on monotherapy and showed the
greatest improvements in pain-related parameters in their
respective group categories.
Conclusion Treatment with pregabalin (as monotherapy
or combination therapy) provides benefits in pain and
treatment satisfaction in patients with NP, including
refractory cases. Shorter disease progression and neuralgia
and PCS etiologies are favorable factors for pregabalin
treatment response.
1 Introduction
Chronic pain affects one in five European adults and represents
a major healthcare problem [1]. Neuropathic pain (NP) is
defined as pain arising from a lesion or disease affecting the
somatosensory pathways within the peripheral or central
nervous system. It usually persists after lesion healing [2–5],
becoming a frequent cause of chronic pain. This type of pain
is difficult to diagnose and treat [5–8]. Chronic pain in
general, and NP specifically, are frequently associated with
anxiety, depression, and sleep disorders [9–12], which not
only contribute to the negative impact of NP on quality of life
[13, 14] but can also negatively affect the response to anal-
gesic treatment. Therapies should therefore treat these con-
comitant symptoms along with pain [15], as recommended
first-line NP treatments (anticonvulsants and tricyclic anti-
depressants) do [16–18]. However, NP management still
represents a therapeutic challenge, especially in refractory
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patients [1, 8]. According to a very recent consensus by a
group of experts, to classify NP as refractory ‘‘it should have
had a trial of treatment with at least four drugs of known
effectiveness, each drug should have been tried for at least
3 months or until side effects prevent adequate dosage, and
despite the above treatment, the intensity of pain should have
been reduced by less than 30% or should remain at a level of
at least 5 on a 0-10 scale and/or it should continue to con-
tribute significantly to poor quality of life’’ [19].
Primary care physicians (PCPs) are usually the first
physicians visited by patients with chronic pain and NP [1,
20–22]. In a previous cross-sectional study conducted in a
Spanish primary care setting, NP prevalence according to
the Douleur Neuropathique en 4 questions (DN4) was
45.7 % in patients with pain visiting primary care centers
[23]. These NP patients experienced moderate pain and
high levels of pain interference with their activities of daily
living and showed little satisfaction with treatment. The
two pharmacologic treatments most frequently used were
non-steroidal anti-inflammatory drugs (NSAIDs) and non-
opioid analgesics (53 and 51 %, respectively), which are
not recommended for NP, while recommended first-line
(anticonvulsants and antidepressants) and second-line
(opioids) treatments [16, 24, 25] were being administered
at lower percentages. Following the previous cross-sec-
tional study, these patients were managed as prescribed by
their physician and followed up for 3 months.
Pregabalin is an anticonvulsant that has been shown to
be effective in randomized clinical trials for a wide array of
painful neuropathic conditions. Pregabalin has level A
evidence for efficacy in patients with postherpetic neural-
gia and painful polyneuropathies [26–28], and has been
shown to be effective in central NP [29] as well as in a
broad range of peripheral NP etiologies [30]. Pregabalin
not only reduces pain but also improves anxiety and pain-
related sleep interference [31–33], and it is safe and
effective in both older and younger patients [34].
In addition, pregabalin is indicated for the treatment of
generalized anxiety disorder (GAD). Pregabalin use is
becoming widespread in psychiatry and addiction-related
treatments. Evidence derived from different studies sug-
gests that pregabalin is an efficacious therapy for GAD [35]
and social anxiety disorder [36], with some preliminary
evidence for its efficacy in relapse prevention. It is also
used as adjunctive therapy in many other psychiatric con-
ditions, such as obsessive compulsive disorder [37], post-
traumatic stress disorder, schizophrenia, bipolar mania
[38], and major depression [39].
Pregabalin has been shown to have positive effects on
benzodiazepine dependence in both the withdrawal phase
and for discontinuation of long-term use, and it is consid-
ered a potentially useful new drug for treatment of alcohol
withdrawal syndrome [40].
Furthermore, pregabalin has been successfully used in
patients with refractory NP [41, 42], which may be the case
in some patients in the current study, since they were
symptomatic despite using a mean 2.4 drugs. Specifically,
in the Spanish primary care setting, pregabalin was shown
to be an effective therapy for the treatment of peripheral
NP in patients refractory to at least one previous analgesic
in routine clinical practice [43, 44]. Therefore, from the
previous cross-sectional study [23], of all the patients fol-
lowed for 3 months, this publication focuses on those who
were treated with pregabalin to confirm the beneficial
effect of this treatment, with the aim of improving the
management of NP. This publication presents original data
as it is a naturalistic study of a large number of patients in
the primary care environment.
2 Methods
Patients from a previous NP prevalence study [23] were
followed up for 3 months to assess the progression of pain-
related parameters and treatment satisfaction. This publi-
cation is a post hoc analysis performed in patients from the
previous NP prevalence study treated with pregabalin [23]
who had not been exposed to the drug in the previous
3 months. The study protocol was approved by the Clinical
Research Ethics Committee of Virgen de las Nieves Hos-
pital (Granada, Spain) in 2008 and complied with all ethical
considerations involving human subjects in accordance
with the Declaration of Helsinki, and followed standard
security and confidentiality measures in compliance with
Spanish legislation.
The aforesaid previous study was an observational,
epidemiologic, cross-sectional, multicenter study carried
out to assess the prevalence of NP according to the DN4 in
primary care centers in Spain, and to characterize NP
patients diagnosed by clinical judgment [23]. All of the
participating physicians (792) enrolled the first 25 patients
over 18 years of age presenting at primary care centers
with pain of any origin and after giving their informed
consent. Of the patients who met the DN4 diagnosis criteria
of NP, the first five with clinical confirmation and who
gave their informed consent were selected and included in
this post hoc analysis. After 57 patients were excluded
because of non-compliance with the screening criteria, this
left a total of 3,836 patients eligible for analysis.
The first 25 patients, 18 years of age or older, seen at
primary care centers for pain of any origin were registered.
The 792 physicians enrolled 16,115 patients complaining
of pain, of whom 7,327 (45.7 %) had NP according to the
DN4. The first five patients with clinically confirmed NP
were recruited after giving their informed consent, result-
ing in a total of 3,893 patients. After excluding 57 for
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non-compliance with screening criteria, 3,836 patients
were eligible to be characterized.
As a post hoc analysis from a previous cross-sectional
study, the decision of the PCP on the most appropriate
medical treatment for his or her patient was never influ-
enced. They were followed up for 3 months to assess the
progression of pain-related parameters and satisfaction with
treatment. In the current post hoc analysis, only patients
treated with pregabalin who had previously not been
exposed to it (patients who had received no treatment or had
been treated with a drug other than pregabalin during the
previous 3 months) were analyzed. The patient disposition
is shown in Fig. 1. These patients had a baseline and a
3-month visit. At baseline, the DN4 questionnaire was
administered and sociodemographic and pain characteristic
(etiology, duration) data were gathered; at baseline and also
at 3 months, Brief Pain Inventory (BPI) Short Form (BPI-
SF), pharmacologic and non-pharmacologic treatment, and
treatment satisfaction data were collected.
2.1 Questionnaires Used
The DN4 [45, 46] is a ten-item questionnaire, which con-
sists of pain descriptors and sensory dysfunctions that are
systematically compared in order to identify patients with a
high probability of NP. Individual item scores are added to
obtain a maximum score of 10, with a screening breakpoint
of 4.
The BPI [47, 48] is a self-administered tool to assess the
intensity of pain and its impact on activities of daily living.
The Spanish version has been validated [51]. The BPI-SF
was used in the current study and was completed by the
patient. The BPI-SF contains 11 items rated on a 0 (no
pain/no interference) to 10 (worst possible pain/total
interference) numeric rating scale, grouped in two dimen-
sions: pain intensity (mean of the first 4 items: worst, least
and average pain during the last week and pain now) and
interference with life activities (mean of the last 7: inter-
ference with general activity, mood, walking ability, nor-
mal work, social relations, and enjoyment of life). Pain
intensity is classified as mild or no pain (0–3), moderate
(4–6), and severe (7). Patients are classified as responders
when pain intensity decreases C50 % from the baseline
score [49, 50].
Satisfaction with treatment was measured by self-
administration of the generic Treatment Satisfaction for
Medication Questionnaire (SATMED-Q) [52]. This ques-
tionnaire consists of 17 items on a Likert-type scale from 0
to 4 points (0 = no, not at all, 1 = somewhat, 2 = mod-
erately, 3 = very, 4 = yes, extremely). The total score is
the mean of the 17 items; scores are standardized from 0 (no
satisfaction at all) to 100 (total or maximum satisfaction).
The 17 items are grouped in six domains or dimensions
(each with 2–3 items) of treatment satisfaction. The domain
explored in the current study was ‘‘overall opinion’’, which
includes items 15 (intention to continue treatment), 16
(feeling at ease with treatment), and 17 (overall satisfaction
with treatment). Scores were also standardized (Z) with
respect to the scores of the normal Spanish population.
2.2 Statistics
Descriptive statistics were applied to all variables, including
measures of central tendency and statistical variability for
quantitative variables, in addition to absolute and relative
frequencies for qualitative variables, at baseline and
3 months, as well as for all changes from baseline. Some data
were missing and results were obtained only from subjects
with available data. Size samples were therefore smaller than
the population sample and differed among variables.
Student’s t-test was used to compare independent data for
quantitative variables and the chi-square test was used for
qualitative variables. For pair-wise data (final scores vs.
baseline), Student’s t-test was used for quantitative variables,
Wilcoxon test for quantitative non-parametric variables, and
McNemar test for dichotomic qualitative variables.
Patients were grouped post hoc according to pain
duration (\1, 1–3, 3–6, 6–12, and [12 months), etiology
[radiculopathy, neuralgia, neuropathy, peripheral nerve
compression syndrome (PCS), complex regional pain
syndrome (CRPS), plexopathy, NP in cancer, central pain,
phantom limb syndrome (PLS) and other by deafferenta-
tion, atypical facial pain, and others] and baseline pain
intensity (mild, moderate, severe). In each group category,
an ANCOVA adjusted for baseline values was performed
to compare changes in among-group scores (BPI-SF,
Test DN4
16,115 registered patients with pain
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Fig. 1 Patient disposition in the previous and current study. DN4
Douleur Neuropathique en 4 questions, NP neuropathic pain
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SATMED-Q, and number of days with no or mild pain).
Only those subjects who had a baseline and a 3-month
score were included.
The statistics program SAS version 8.2 (SAS Institute
Inc., Cary, NC, USA) was used for all statistical analysis
and all statistics tests were bilateral with significance levels
of 5 %.
3 Results
Of 3,836 NP patients from a previous prevalence study in
the Spanish primary care setting, 3,516 (91.7 %) completed
the study. Reasons for dropping out (8 %) were lost to
follow-up (84; 2.2 %), at patient’s request (54; 1.4 %),
researcher’s decision (35; 0.9 %), death (17; 0.4 %),
adverse events (16; 0.4 %), exacerbation of disease (13;
0.3 %), unknown reasons (40; 1 %), protocol violations (8;
0.2 %), and other reasons (59; 1.5 %). Of 3,516 patients,
1,670 were treated with pregabalin for 3 months who had
not been exposed to the drug in the previous 3 months [173
patients (10.4 %) had not received any treatment and 1,497
(89.6 %) had been treated with at least one drug other than
pregabalin]. Fifty-nine percent were women, mean age was
58 years, and 71 % were overweight (Table 1). Patients
had taken the DN4 questionnaire with a mean number of
six positive answers. Pain had been chronic for almost a
year. The most frequent etiology was radiculopathy (55 %)
and the most frequent NP diagnosis was lumbar spinal cord
and nerve root disorders (22 %).
This subgroup of 1,670 patients treated with pregabalin
(average dose 202 mg/day) are the target sample group of
this post hoc analysis. Of those 1,670 patients, 617 (36.9 %)
were taking pregabalin monotherapy, 517 (30.9 %) received
one concomitant treatment, and 536 (32.1 %) received two
or more (up to 5). The mean number of drugs used ‘‘within
3 months before the study’’ was 2.2 ± 1.1 and ‘‘during the
study’’ was 2.1 ± 1.1. Three months before the study, an-
ticonvulsants were used in only 9 % of patients, with
gabapentin as the only glutamate and GABA analog, and the
most frequently used pharmacologic treatments were
NSAIDs (61 %) and non-opioid analgesics (58 %), both
reduced by half during the course of the study (Table 2).
Non-pharmacologic treatment was used in 43.4 % of
patients in the previous 3 months and in 34.3 % during the
study, with physiotherapy and local administration of heat
being the most frequent ones used in both periods.
Figure 2 and Table 3 show the progression of pain
parameters and satisfaction with treatment from baseline to
the end of the study. After adjusting for baseline scores,
pain intensity and its interference with activities were
significantly (p \ 0.0001) reduced by half, while the
number of days with no or mild pain increased by a mean
of 4.5 days (p \ 0.0001). There were 843 (51.6 %)
responders (patients whose pain intensity decreased by
C50 %) (data not shown), 22 % of patients had severe pain
and 75 % moderate pain at baseline, and these percentages
decreased to 1 and 31 %, respectively, at 3 months. The
proportion of patients with no or mild pain, which was 3 %
at baseline, increased to 67 % (data not shown). Regarding
satisfaction with treatment, the overall opinion doubled
(from 35.2 to 76.8; p \ 0.0001), and the standardized score
rose to the level of the general population at 3 months of
treatment (p \ 0.0001), from 2 points below at baseline.
3.1 Progression According to Pain Duration
Patients were divided according to their pain dura-
tion:\1 month (356 patients), 1–3 months (226), 3–6 months
(292), 6–12 months (308) and[12 months (430) groups.
The mean number of drugs administered during the study
was significantly (p = 0.0025) different among groups,
Table 1 Socio-demographic characteristics of the target sample
population (3,836 patients)
Women 981 (59.4)
Age (years) 58.5 ± 13.7
Bodyweight (kg) 74.2 ± 11.9
Height (cm) 165 ± 8.5
BMI (kg/m2) 27.2 ± 3.9
B18.5 (low weight) 7 (0.4)
18.5–25 (normal weight) 474 (28.7)
25–30 (obesity grade I) 816 (49.5)
30–35 (obesity grade II) 301 (18.2)
35–40 (obesity grade III) 41 (2.5)
C40 (obesity grade IV) 11 (0.7)
DN4 positive questions (no.) 6.3 ± 1.5
Pain duration (years) 0.9 ± 1.8





Peripheral nerve compression syndrome 178 (10.71)
Complex regional pain syndrome 53 (3.2)
Plexopathy 44 (2.6)
Other 43 (2.6)
Central pain 29 (1.7)
Oncology-associated pain 27 (1.6)
Phantom limb syndrome and other deafferentation
pain
16 (1.0)
Atypical facial pain 13 (0.8)
Values expressed as n (%) or mean ± SD
BMI Body Mass Index, DN4 Douleur Neuropathique en 4 questions
a Some patients indicated more than one etiology
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ranging from 2.0 in the \1 month group to 2.3 in
the [12 months group. There were also significant differ-
ences (p = 0.0211) in the proportion of patients on pregab-
alin monotherapy or combination therapy among groups,
with the groups with shorter disease progression showing
higher patient percentages on monotherapy: 40 % in the
\1 month group, 43 % in 1–3 months, 38 % in 3–6 months,
37 % in 6–12 months, and 31 % in[12 months.
From baseline to the endpoint, pain intensity and inter-
ference with daily life decreased significantly (p \ 0.0001)
and the number of days with no or mild pain increased
significantly (p \ 0.0001) within each group. Among-group
significant differences (p \ 0.0001) were observed for
changes in the adjusted scores of the three parameters, with
the\1 and 1–3 months groups showing the largest decrea-
ses in pain intensity and pain interference with daily activ-
ities and the largest increases in number of days with no or
mild pain (Table 4; Fig. 3a, b). Significant (p \ 0.0001)
differences were also observed among groups in the pro-
portion of responders, which decreased as the duration of
pain increased (Fig. 3c). The overall within-group opinion
of satisfaction with treatment increased significantly
(p \ 0.0001) and the among-group changes were signifi-
cantly (p = 0.0386) different, with the 1–3 and \1 month
groups showing the largest increases (Fig. 3d); the within-
group changes for the standardized score were also signifi-
cant (p \ 0.0001) and significant (p = 0.0362) differences
were observed in the among-group changes, with the
1–3 months group showing the highest increase (Fig. 3e).
3.2 Progression According to Etiology
Patients were divided according to their pain etiology into
radiculopathy (841 patients), neuralgia defined as pain in
Table 2 Treatments used previously (within 3 months before the






Pregabalin – 1,670 (100)
Gabapentin 87 (5.8) 17 (1.0)
Carbamazepine 37 (2.5) –
NSAIDs
Ibuprofen 411 (27.5) 183 (10.0)
Diclofenac 286 (19.1) 104 (6.2)
Dexketoprofen 59 (3.9) 30 (1.8)
Aceclofenac 45 (3.0) 18 (1.1)
Celecoxib 37 (2.5) 41 (2.5)
Naproxen 37 (2.5) 19 (1.1)
Meloxicam 21 (1.4) –
Aspirin 18 (1.2) –
Non-opioid analgesic
Paracetamol 620 (41.4) 374 (22.4)
Metamizol 268 (17.9) 128 (7.7)
Opioid
Tramadol 248 (16.6) 158 (9.5)
Fentanyl 30 (2.0) 30 (1.8)
Non-opioid analgesic/opioid combination
Paracetamol/tramadol 69 (4.6) 68 (4.1)
Codeine/paracetamol 15 (1.0) –
Benzodiazepine
Tetrazepam 124 (8.3) 48 (2.9)
Lorazepam 20 (1.3) 24 (1.4)
Alprazolam 16 (1.1) –
Diazepam – 55 (3.3)
Antidepressant
Amitriptyline 79 (5.3) 51 (3.1)
Paroxetine 15 (1.0) –
Other
Omeprazole 70 (4.7) 55 (3.3)
Hydroxocobalamin/pyridoxine/
thiamine
29 (1.9) 18 (1.1)
Metformin 24 (1.6) 19 (1.1)




Pantoprazole 19 (1.3) 18 (1.1)
Pharmacologic groupsa
NSAIDs 907 (60.6) 428 (25.6)
Non-opioid analgesics 864 (57.7) 535 (32)
Opioids 362 (24.2) 265 (15.9)
Anticonvulsants 136 (9.1) 1,670 (100)
Antidepressants 133 (8.9) 108 (6.5)
Benzodiazepines 259 (17.3) 153 (9.2)







Any 674 (43.4) 502 (34.3)
Physiotherapyb 328 (48.7) 294 (58.6)
Local administration of heatb 368 (54.6) 204 (40.6)
Local administration of coldb 71 (10.5) 38 (7.6)
Vibrations/massagesb 121 (18.0) 78 (15.5)
Acupunctureb 69 (10.2) 28 (5.6)
Otherb 60 (8.9) 45 (9.0)
Data expressed as n (%) patients
NSAIDs non-steroidal anti-inflammatory drugs
a Some drugs are classified in more than one group
b Percentage based on the total number of patients using any non-
pharmacologic treatment
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the distribution of a nerve or nerves (265), neuropathy
defined as a disturbance of function or pathologic change in
a nerve (161), PCS (142), CRPS (32), plexopathy (27),
NP in cancer (21), central pain (19), PLS and other
deafferentation pain (13), atypical facial pain (11), and
others (35).
The mean number of drugs used during the study was
significantly (p = 0.001) different among groups, with
‘‘NP in cancer’’ having the highest number (2.8) and
‘‘atypical facial pain’’ the lowest (1.8). There were also
significant differences (p = 0.0447) in the proportions of
patients on pregabalin monotherapy or combination therapy
among groups. The proportions of patients on monotherapy
were as follows: NP in cancer 19 %, PLS and other
deafferentation pain 23 %, other 31 %, central pain 32 %,
CRPS 34 %, radiculopathy 35 %, atypical facial pain
36 %, neuropathy 37 %, plexopathy 41 %, neuralgia 45 %,
and PCS 46 %.
As it is the most prevalent group, it is worth noting that
in the group of patients with radiculopathy as the cause of
NP, of the 841 patients who reported radicular NP, 65 %
were treated with pregabalin as part of a combination
therapy and 35 % with pregabalin alone.
Regarding the pregabalin add-on group, more than half
took a combination with one other drug (52 %) and 32 %
received two other drugs, while 10 % received a combi-
nation of pregabalin plus three other drugs (mean number

















































































































































































Fig. 2 Progression of pain parameters and satisfaction with treatment
during the study: a change in mean ± SD baseline-adjusted BPI-SF
scores for pain intensity and pain interference with activities;
b change in mean ± SD baseline-adjusted number of days with no
or mild pain in the last week; c mean ± SD overall opinion score for
satisfaction with treatment (SATMED-Q) at baseline and 3 months
(baseline-adjusted); d mean ± SD overall opinion score for satisfac-
tion with treatment (SATMED-Q) standardized for the Spanish
population at baseline and 3 months. All p values vs. baseline. BPI-
SF Brief Pain Inventory-Short Form, SATMED-Q Treatment Satis-
faction for Medication Questionnaire, SD standard deviation
Table 3 Pain-related parameters and satisfaction with treatment at baseline and endpoint (3 months)
Outcomes n Baseline 3 months Change (95 % CI) p value
BPI-SF
Pain intensity (score) 1,636 6.4 ± 1.5 2.9 ± 1.7 -3.5 (-3.6 to -3.4) \0.0001
Interference with activities (score) 1,621 6.3 ± 1.8 2.8 ± 2 -3.5 (-3.6 to -3.4) \0.0001
No or mild pain last week (days) 1,647 0.3 ± 1.4 4.8 ± 3.3 4.5 (4.3–4.7) \0.0001
SATMED-Q
Overall satisfaction (score) 1,517 35.2 ± 24.4 76.8 ± 17.5 41.6 (40.1–43) \0.0001
Standardized overall satisfaction (Z score) 1,502 -2.0 ± 1.1 -0.0 ± 0.8 1.9 (1.9–2.0) \0.0001
Data are observed means ± SD with 95 % confidence intervals; p values are adjusted by baseline values
BPI-SF Brief Pain Inventory Short Form, SATMED-Q Treatment Satisfaction for Medication Questionnaire
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Thirty-four percent of the patients received at least one
non-opioid analgesic, 31 % took NSAIDs, 15 % took
opioids, and 12 % took benzodiazepines.
Pain intensity and interference with daily life decreased
(p \ 0.0001), while the number of days with no or mild
pain increased (p \ 0.0001) significantly within groups
at 3 months. Significant among-group differences
(p \ 0.0001) were observed for the changes in the adjusted
scores of pain intensity, interference with activities, and
days with no or mild pain, with neuralgia and PCS groups
showing the largest changes in all three parameters
(Table 5; Fig. 4a, b). Significant (p = 0.0002) differences
in the number of responders were observed among groups,
with the CRPS (65.6 %) and neuralgia (62.9 %) groups
showing the highest percentages of responders (Fig. 4c).
Regarding satisfaction with treatment, there were sig-
nificant among-group differences at baseline on the scores
obtained on the three questions of the SATMED-Q overall
opinion domain. On ‘‘Intention to continue treatment’’
(p \ 0.0001), scores ranged from 1.2 ± 1.0 to 2.1 ± 1.1;
on ‘‘Feeling at ease with treatment’’ (p = 0.0014), from
0.9 ± 1.0 to 1.7 ± 1.0; and on ‘‘Overall satisfaction with
treatment’’ (p = 0.0060), from 0.9 ± 0.8 to 1.6 ± 1.2.
After 3 months of pregabalin treatment, the scores for
‘‘Intention to continue treatment’’ were similar among
groups (p = 0.0741), ranging from 2.8 ± 1.1 to 3.5 ± 0.5.
The scores for ‘‘Feeling at ease with treatment’’ were sig-
nificantly different (p = 0.0039) among groups, ranging
from 2.6 ± 1.1 to 3.2 ± 0.8, with neuralgia and PLS
showing the highest mean score. The scores for ‘‘Overall
satisfaction with treatment’’ were also significantly different
(p = 0.0011), ranging from 2.7 ± 1.1 to 3.3 ± 0.7, with
neuralgia showing the highest mean score (data not
shown).
3.3 Progression According to Baseline Pain Intensity
Patients were divided according to their baseline pain
intensity as mild or no pain (364 patients), moderate
(1,120), and severe (364).
Significant differences were observed in the mean
number of drugs administered during the study
(p = 0.0012) among groups, with the severe pain group
having the highest number (2.3) and the no or mild pain
group the lowest (1.9), but the proportion of patients on
pregabalin monotherapy or on combination therapy was
similar (p = 0.4028) among groups.
The adjusted scores for pain intensity and pain inter-
ference with activities decreased significantly (p \ 0.0001)
within groups but the changes were similar among groups
Table 4 Outcomes according to pain duration
Outcomes \1 month 1–3 months 3–6 months 6–12 months [12 months p valueb
(n = 355) (n = 226) (n = 296) (n = 309) (n = 432)
BPI-SF score for pain intensity
Baseline, mean [SD] 6.5 [1.5] 6.3 [1.4] 6.3 [1.4] 6.4 [1.4] 6.3 [1.5] 0.2198
Change (95 % CI) -4.5 (-4.7 to -4.3) -3.8 (-4.0 to -3.5) -3.3 (-3.5 to -3.1) -3.3 (-3.5 to -3.1) -2.8 (-3.0 to -2.6) \0.0001
p valuea \0.0001 \0.0001 \0.0001 \0.0001 \0.0001
BPI-SF score for pain interference with activities
Baseline, mean [SD] 6.1 [1.9] 6.0 [1.8] 6.3 [1.7] 6.4 [1.8] 6.5 [1.8] 0.0002
Change (95 % CI) -4.2 (-4.4 to -4.0) -3.6 (-3.9 to -3.4) -3.6 (-3.8 to -3.3) -3.5 (-3.7 to -3.2) -3.0 (-3.2 to -2.8) \0.0001
p valuea \0.0001 \0.0001 \0.0001 \0.0001 \0.0001
Number of days with no or mild pain
Baseline, mean [SD] 0.3 [1.5] 0.2 [1.2] 0.3 [1.3] 0.3 [1.5] 0.3 [1.3] 0.8402
Change (95 % CI) 5.7 (5.4–6.0) 5.0 (4.6–5.4) 4.7 (4.4–5.1) 4.2 (3.8–4.5) 3.5 (3.2–3.8) \0.0001
p valuea \0.0001 \0.0001 \0.0001 \0.0001 \0.0001
Overall opinion score for satisfaction with treatment (SATMED-Q)
Baseline, mean [SD] 30.7 [26.1] 34.8 [25.5] 36.2 [23.0] 34.1 [23.5] 38.5 [23.9] 0.001
Change (95 % CI) 47.8 (44.2–51.4) 44.4 (40.7–48.1) 41.7 (38.4–45.0) 42.1 (39.0–45.3) 36.6 (33.7–39.5) 0.0386
p valuea \0.0001 \0.0001 \0.0001 \0.0001 \0.0001
Overall opinion score for satisfaction with treatment (SATMED-Q) standardized for the Spanish population
Baseline, mean [SD] -2.2 [1.2] -2 [1.2] -1.9 [1.1] -2 [1.1] -1.8 [1.1] 0.001
Change (95 % CI) 2.2 (2.1–2.4) 2.1 (1.9–2.3) 1.9 (1.8–2.1) 2.0 (1.8–2.1) 1.7 (1.6–1.8) 0.0362
p valuea \0.0001 \0.0001 \0.0001 \0.0001 \0.0001
BPI-SF Brief Pain Inventory-Short Form, SATMED-Q Treatment Satisfaction for Medication Questionnaire
a Data are observed means ± SD with 95 % confidence intervals; p values are adjusted by baseline values and represent within-group comparisons
b Data are observed means ± SD with 95 % confidence intervals; p values are adjusted by baseline values and represent between-group comparisons
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(p = 0.2047 for pain intensity and p = 0.9956 for pain
interference with activities) (Table 6; Fig. 5a). Likewise,
there were significant (p \ 0.0001) within-group increases
in the number of days with no or mild pain; however, the
change in number of days was significantly (p \ 0.0001)
different among groups, increasing in size as the intensity
of baseline pain decreased (Table 6; Fig. 5b). Regarding
satisfaction with treatment, the adjusted overall opinion
scores increased significantly (p \ 0.0001) within groups
but no significant (p = 0.4204) among-group changes were
observed (data not shown).
4 Discussion
A cross-sectional study carried out in the primary care
setting [23] highlighted the non-appropriate management
of NP patients, with over half of them being treated with
NSAIDs and non-opioid analgesics. Patients had moderate
pain intensity and interference with activities, and although
many were inappropriately treated, others may have been
treatment-refractory cases. These patients were treated for
3 months at the discretion of their physicians, and we
focused on those treated with pregabalin, since this treat-
ment had been shown to be effective in NP patients
refractory to at least one previous analgesic in the Spanish
primary care setting [43, 44]. Data obtained (significant
reduction in pain intensity and interference with activities
and significant increase in overall satisfaction with treat-
ment) confirmed the beneficial effect of pregabalin as
monotherapy or combination therapy in this setting.
The target pregabalin-unexposed population demo-
graphically reflected the overall NP population, since 59 %
were women and the mean age was 58 years, in keeping
with previous Spanish and European studies showing that
women and middle-age patients suffer more frequently
from NP [12, 53, 54]. Radiculopathy was also the most
frequent etiology (55 %) in this population, as is the case in
the overall NP population in Spanish pain units [53].
Pregabalin treatment as monotherapy and combination
therapy was effective in pregabalin-unexposed patients,
most (90 %) of whom were previously treated with at least
one other treatment. At 3 months of treatment, pain




































































































































































































































Fig. 3 Pain outcomes according to disease progression: a change in
mean baseline-adjusted BPI-SF scores for pain intensity and pain
interference with activities; b change in mean baseline-adjusted
number of days with no or mild pain; c responders to treatment;
d change in baseline-adjusted overall opinion score for satisfaction
with treatment (SATMED-Q); e mean baseline- and endpoint-
adjusted overall opinion score for satisfaction with treatment (SAT-
MED-Q) standardized for the Spanish population. p values represent
among-group differences. BPI-SF Brief Pain Inventory-Short Form,
SATMED-Q Treatment Satisfaction for Medication Questionnaire
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significantly reduced, resulting in a significant increase in
the number of days with no or mild pain. The percentage of
responders (51.6 %) was closer to that observed in patients
receiving pregabalin in the study by Navarro et al. [44]
(55 % overall; including 52.1 % of responders to
pregabalin combination therapy and 57.9 % of responders
to pregabalin monotherapy). As a result of the pain
reduction by half, satisfaction with treatment (overall
opinion) doubled, with the standardized score reaching the


























































































Fig. 4 Pain outcomes according to etiology: a change in mean
baseline-adjusted BPI-SF scores for pain intensity and pain interfer-
ence with activities; b change in mean baseline-adjusted number of
days with no or mild pain; c responders to treatment. p values
represent among-group differences. BPI-SF Brief Pain Inventory-
Short Form, CRPS complex regional pain syndrome, PCS peripheral
nerve compression syndrome, PLS phantom limb syndrome
Table 6 Outcomes according to baseline pain intensity
Outcomes Intense Moderate No or mild p valueb
(n = 364) (n = 1,220) (n = 52)
BPI-SF score for pain intensity
Baseline mean [SD] 8.3 [0.5] 6 [1.0] 2.6 [0.7] \0.0001
Change (95 % CI) -4.9 (-5.1 to -4.7) -3.2 (-3.3 to -3.1) -1.2 (-1.5 to -0.9) 0.2047
p valuea \0.0001 \0.0001 \0.0001
BPI-SF score for pain interference with activities
Baseline mean [SD] 7.7 [1.2] 6 [1.6] 2.9 [1.6] \0.0001
Change (95 % CI) -4.4 (-4.6 to -4.1) -3.4 (-3.5 to -3.3) -1.5 (-1.9 to -1.1) 0.9956
p valuea \0.0001 \0.0001 \0.0001
Number of days with no or mild pain
Baseline mean [SD] 0 [0.0] 0.1 [0.9] 6.2 [2.3] \0.0001
Change (95 % CI) 3.9 (3.5 to 4.3) 4.8 (4.7 to 5.0) 0.7 (-0.0 to 1.4) \0.0001
p valuea \0.0001 \0.0001 \0.0001
BPI-SF Brief Pain Inventory-Short Form, SD standard deviation
a Data are observed means ± SD with 95 % confidence intervals; p values are adjusted by baseline values and represent within-group
comparisons
b Data are observed means ± SD with 95 % confidence intervals; p values are adjusted by baseline values and represent between-group
comparisons
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Patients with shorter disease progression (B3 months)
and those with neuralgia and PCS etiology seemed to
respond better to pregabalin treatment. The possibility of
distinct NP subtypes depending on etiology has been dis-
cussed [55]. The study by Attal et al. [55] investigating the
relationship between positive NP symptoms and etiologies
found some associations, such as the association of tri-
geminal neuralgia and postherpetic neuralgia with absence
of tingling and pins and needles, and that of amputation
pain and plexopathy with presence of electric shocks and
stabbing pain. Thus, neuralgia may be a distinct NP sub-
type with better response to pregabalin than other etiolo-
gies, and so may be the case for PCS. Regarding pain
duration, a short duration between symptom onset and
treatment has already been associated with NP improve-
ment in other neuropathy cases [56]. On the other hand, it
is important to point out that those groups were also the
ones with the highest proportion of patients on pregabalin
monotherapy. Combination treatment is usual clinical
practice in NP and may result in greater pain relief [57];
however, these groups showed better treatment response
despite being the ones with the lowest proportion of
patients on combination therapy. Pregabalin monotherapy
may be more effective than combination therapy in these
patients. In the study by Navarro et al. [44], at least
numerically, there were more responders in the pregabalin
monotherapy group than in the combination therapy group
(57.9 vs. 52.1 %). Therefore, we cannot establish how
much of the among-group change differences observed are
due to time since disease onset and etiology type and how
much to the proportion of monotherapy/combination
therapy.
The per baseline pain intensity groups, which had
similar proportions of patients on combination therapy or
monotherapy, did not show any significant among-group
differences in the score changes for pain intensity, inter-
ference with activities, and satisfaction with treatment.
These data seem to support the possible effect of mono-
therapy or combination therapy over treatment response,
since among-group changes were significantly different
only in group categories with significantly different per-
centages of monotherapy and combination therapy among
groups. However, having no or mild pain at baseline still
resulted in more pain-free (or mild pain) days after
3 months of pregabalin treatment, which suggests a posi-
tive association between low baseline pain intensity and
pregabalin treatment response.
Overall, at 3 months, satisfaction with treatment seemed
to be improved, since the lowest mean score for each
SATMED-Q overall opinion question was higher than the
highest score for that same question at baseline. Patients
with neuralgia seemed to be the most satisfied with pre-
gabalin treatment, in keeping with the largest improvement
in pain intensity, interference with daily life, and number of
days with no or mild pain in this group.
Our study has some limitations. The observational
design introduces different confounding factors including
‘‘confounding by indication’’, where prognostic factors
may influence treatment decisions [58, 59]. Also, psychiatric
co-morbidities were not assessed and this could influence
the outcomes.
The current post hoc analysis assessed only patients
treated with pregabalin; however, in the analyses of the per
pain duration and per etiology groups, the proportion of
patients receiving monotherapy or combination therapy
differed among groups, which may act as another con-
founding factor for the outcomes observed. This will have
to be further analyzed. Also, in each group category,
baseline values were significantly different among groups
for most variables. However, the analyses were adjusted for
baseline values to even out possible bias. Since we focused
on pregabalin-treated patients, outcomes could not be
compared with those of patients on other treatments;
however, in the study by Navarro et al. [43, 44], patients on
pregabalin monotherapy or combination therapy showed
greater reductions in pain severity than those on non-PGB
therapy.
Whether or not the proportion of patients on mono-
therapy or combination therapy influences the outcomes,









































































Fig. 5 Pain outcomes according to baseline BPI-SF pain intensity:
a change in mean baseline-adjusted BPI-SF scores of pain intensity
and pain interference with activities; b change in mean baseline-
adjusted number of days with no or mild pain. p values represent
among-group differences. BPI-SF Brief Pain Inventory-Short Form
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NSAIDs (32 and 26 % of all patients) as concomitant
treatments, and only 22 % were treated with another NP
recommended treatment (antidepressants or opioids); thus,
in most patients (78 %) the reduction in pain intensity and
interference with activities observed is most likely due to
pregabalin.
5 Conclusion
Our analysis suggests that treatment with pregabalin, both
as monotherapy or in combination with other drugs, pro-
vides benefits for pain and treatment satisfaction in patients
with NP, including refractory cases. Shorter disease pro-
gression, neuralgia and PCS etiologies, and low baseline
pain intensity seem to be favorable variables for pregabalin
treatment response. The possible effect of monotherapy or
combination therapy on treatment response should be fur-
ther investigated.
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